Nussbaum, Robert L.
Haverfield, Eden
Esplin, Edward D.
Aradhya, Swaroop
Article History
Received: 2 May 2019
Accepted: 28 May 2019
First Online: 26 June 2019
Disclosure
: All authors are employees and stock holders in Invitae, a commercial genetic testing company that has pioneered the use of genetic testing of unaffected individuals seeking to know their risk for serious, unsuspected yet actionable oncological and cardiovascular disorders. In addition, RLN is a consultant for Pfizer Pharmaceuticals, and a consultant and stock holder in Maze Therapeutics and Genome Medical.